5 / 36
FEATURES – Q & A
32 Emergin g Science in Gliomas and Glioblastomas: A Review 33 Current Concepts in Stem Cell Transplantation for Multiple Myeloma 34 New Da ta on Immunotherapy for Bladder Cancer: Part 1CONFERENCE
14 ESMO 2 017 CongressCOVER
10 Effect o f Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With AtherosclerosisRESEARCH
Editor’s picks
6 Noninferiority of Partial-Breast and Reduced-Dose Radiotherapy After Breast Conservation Surgery for Patients With Early Breast CancerComment by Noam VanderWalde MD
7 The BRCA1ness Signature is Associated Significantly With Response to PARP Inhibitors in the I-SPY 2 Randomized Neoadjuvant Setting 8 Improved Efficacy of Palbociclib vs Chemotherapy for the Treatment of Postmenopausal Women With HR+/HER2− Advanced/Metastatic Breast CancerComment by Lee S. Schwartzberg MD, FACP
9 Neratinib Efficacy and ctDNA Detection of HER2 Mutations in HER2 Non-Amplified Metastatic Breast CancerComment by Reshma L. Mahtani DO
10 Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With AtherosclerosisComment by Peter Libby MD
11 Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic LeukemiaGeneral oncology
26 Direct Detection of Early-Stage Cancers Using Circulating Tumor DNAComment by Erin Schenk MD, PhD
27 Use of Alternative Medicine for Cancer Associated With Increased MortalityBreast
28 Adjuvant Tamoxifen and Exemestane in Women With Postmenopausal Early Breast CancerComment by Annette Hasenburg Prof. Dr. med
29 Ipatasertib Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast CancerComment by Lee S. Schwartzberg MD, FACP
Hematology
30 Lenalidomide vs Placebo Maintenance After Single ASCT for Multiple MyelomaComment by Rafael D. Fonseca MD
31 Novel Composite Model to Estimate Risk of Mortality in AML 31 Long-Term Follow-Up of Chemoimmunotherapy With Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone in Patients With Relapsed CD20+ B-Cell NHL 14 Nutritional Status and Treatment Response: An Update 15 Abiraterone Acetate Plus Prednisolone Comparable to Docetaxel in High-Risk Prostate Cancer 16 New Data on Anti-Emesis Agents 16 Updates in the Management of GBM 17 New Data on the Management of HCC 20 MONARCH 3: Abemaciclib Improves Progression-Free Survival in Endocrine- Sensitive Advanced Breast Cancer 21 Systemic Immune-Inflammation Index, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio are Robust Predictors of Outcome of Nivolumab Therapy for Metastatic Renal Cell Carcinoma 22 Three Months of Oxaliplatin-Based Chemotherapy Usually Suffices, With Less Neurotoxicity Than 6 Months, in Stage 3 Colon Cancer 23 Cabozantinib Is Safe and Effective for Metastatic Renal Cell Carcinoma in Real- World Practice 24 MicroRNAs Are Identified as Possible Biomarkers of Outcome With Bevacizumab in Metastatic Breast CancerCONTENTS
5
VOL. 1 • NO. 3 • 2017